Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PRKCA | P17252 | 6/20 | 0.42 |
| ▸ | DGKA | P23743 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9435100 | 0.95 | NAAA (0.62) | NAAASMN1; SMN2PKMMAPTPRKCA | |
| SCHEMBL9435112 | 0.95 | NAAA (0.62) | NAAASMN1; SMN2PKMMAPTPRKCA | |
| SCHEMBL9435105 | 0.95 | NAAA (0.62) | NAAASMN1; SMN2PKMMAPTPRKCA | |
| SCHEMBL10824055 | 0.95 | NAAA (0.62) | NAAASMN1; SMN2PKMMAPTPRKCA | |
| SCHEMBL9435056 | 0.94 | NAAA (0.65) | NAAASMN1; SMN2PRKCADGKAMEN1 | |
| SCHEMBL9435046 | 0.94 | NAAA (0.65) | NAAASMN1; SMN2PRKCADGKAMEN1 | |
| SCHEMBL10707353 | 0.94 | NAAA (0.65) | NAAASMN1; SMN2PRKCADGKAMEN1 | |
| SCHEMBL10709862 | 0.94 | NAAA (0.65) | NAAASMN1; SMN2PRKCADGKAMEN1 | |
| SCHEMBL10702534 | 0.94 | NAAA (0.65) | NAAASMN1; SMN2PRKCADGKAMEN1 | |
| SCHEMBL10703264 | 0.94 | NAAA (0.65) | NAAASMN1; SMN2PRKCADGKAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348359-A1 | IONIZABLE LIPIDS FOR NANOMATERIALS | BEAM THERAPEUTICS INC. (US) | 2023-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348359-A1 | IONIZABLE LIPIDS FOR NANOMATERIALS | PHOSPHO1, SGMS2, SGMS1 | NAAA 1055/4885SMN1; SMN2 2269/4885PKM 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.